Why IMU is a multi multi bagger, page-25966

old timer Dingo, was not sure if this will excite the market like last time... investors, punters and influencers have moved on I guess, but from my blurb below is the extract

1. HER-Vaxx:Clinical Trial Results: The final analysis of the Phase 2 HERIZON trial demonstrated a significant improvement in overall survival (OS) when HER-Vaxx was combined with standard chemotherapy for patients with HER2-neu overexpressing advanced gastric and gastroesophageal junction cancer. The treatment showed a 41.5% reduction in the risk of death compared to chemotherapy alone, with a favorable safety profile and no serious adverse reactions reported
   

   • Future Development: The HERIZON-extension trial approved a higher 100 μg dose for future studies, which is expected to generate improved clinical responses.

2. PD1-Vaxx:

   • Clinical Trial Progress: PD1-Vaxx is in Phase 1 trials, focusing on its safety and tolerability in non-small cell lung cancer (NSCLC) patients. The trial has successfully dose-escalated without encountering dose-limiting toxicities, suggesting a favorable safety profile

Potential Success of These Products:

Both HER-Vaxx and PD1-Vaxx have shown promising early-stage results in their respective trials, indicating strong potential for further development. HER-Vaxx, in particular, has demonstrated a significant survival benefit, which could position it well for future regulatory approval and market success. PD1-Vaxx's ongoing trials will need to confirm efficacy to advance further, but its initial safety data is encouraging. Continued success in these trials could positively impact Imugene's market position and stock price